Neurogene Inc.
NGNE
$19.98
-$0.01-0.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | 925.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | 925.00K |
| Cost of Revenue | 19.37M | 17.76M | 15.35M | 16.29M | 15.74M |
| Gross Profit | -19.37M | -17.76M | -15.35M | -16.29M | -14.82M |
| SG&A Expenses | 6.72M | 8.16M | 6.17M | 5.90M | 5.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.08M | 25.92M | 21.51M | 22.18M | 21.06M |
| Operating Income | -26.08M | -25.92M | -21.51M | -22.18M | -20.13M |
| Income Before Tax | -22.02M | -22.65M | -19.51M | -20.22M | -18.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.02M | -22.65M | -19.51M | -20.22M | -18.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.02M | -22.65M | -19.51M | -20.22M | -18.49M |
| EBIT | -26.08M | -25.92M | -21.51M | -22.18M | -20.13M |
| EBITDA | -25.31M | -25.16M | -20.71M | -21.37M | -19.32M |
| EPS Basic | -1.05 | -1.08 | -1.00 | -1.19 | -1.09 |
| Normalized Basic EPS | -0.65 | -0.67 | -0.63 | -0.75 | -0.68 |
| EPS Diluted | -1.05 | -1.08 | -1.00 | -1.19 | -1.09 |
| Normalized Diluted EPS | -0.65 | -0.67 | -0.63 | -0.75 | -0.68 |
| Average Basic Shares Outstanding | 21.06M | 21.00M | 19.47M | 16.95M | 16.94M |
| Average Diluted Shares Outstanding | 21.06M | 21.00M | 19.47M | 16.95M | 16.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |